DNA variation in a 13-mb region including the F9 gene: Inferring the genealogical history and causal role of a hemophilia B mutation (IVS 5+13 A→G)

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 12, 2003, Pages 2609-2614

  Anagnostopoulos, T ^a   Morris, A P ^b   Ayres, K L ^c   Giannelli, F ^a   Green, P M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF READING   (United Kingdom)

Author keywords

B; Founder intronic mutation; H.; Hemophilia; Shattered coalescent modelling

Indexed keywords

BLOOD CLOTTING FACTOR 9;

ARTICLE; BAYES THEOREM; EPIDEMIOLOGY; FOUNDER EFFECT; GENETIC VARIABILITY; GENETICS; HEMOPHILIA B; HUMAN; MISSENSE MUTATION; MOLECULAR EVOLUTION; NUCLEOTIDE SEQUENCE; PEDIGREE; PREVALENCE; UNITED KINGDOM;

BASE SEQUENCE; BAYES THEOREM; CAUSALITY; DNA MUTATIONAL ANALYSIS; EVOLUTION, MOLECULAR; FACTOR IX; FOUNDER EFFECT; GREAT BRITAIN; HEMOPHILIA B; HUMANS; MUTATION, MISSENSE; PEDIGREE; PREVALENCE; VARIATION (GENETICS);

EID: 1542649931     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2003.00514.x     Document Type: Article

References (24)

1. Morris AP, Whittaker JC, Balding DJ. Fine scale mapping of disease loci via shattered coalescent modeling of genealogies. Am J Hum Genet 2002; 70: 686-707.
2. Francis RB, Kasper CK. Reproduction in hemophilia. JAMA 1983; 250: 3192-5.
3. Green PM, Naylor JA, Giannelli F. The hemophilias. Adv Genet 1995; 32: 99-139.
4. Thompson AR, Bajaj SP, Chen SH, MacGillivray RT. 'Founder' effect in different families with hemophilia B mutation. Lancet 1990; 335: 418.
5. Ketterling RP, Bottema CD, Phillips JA 3rd, Sommer SS. Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States. Genomics 1991; 10: 1093-6.
6. Thorland EC, Weinshenker BG, Liu JZ, Ketterling RP, Vielhaber EL, Kasper CK, Ambriz R, Paredes R, Sommer SS. Molecular epidemiology of factor IX germline mutations in Mexican Hispanics: pattern of mutation and potential foundereffects. Thromb Haemost 1995; 74: 1416-22.
7. Morgan GE, Figueiredo MS, Winship PR, Baker R, Bolton-Maggs PH, Brownlee GG. The high frequency of the -6G→A factorIX promoter mutation is the result both of a founder effect and recurrent mutation at a CpG dinucleotide. Br J Haematol 1995; 89: 672-4.
8. Saad S, Rowley G, Tagliavacca L, Green PM, Giannelli F. First report on UK database of hemophilia B mutations and pedigrees. UK Hemophilia Centers. Thromb Haemost 1994; 71: 563-70.
9. Shapiro MB, Senapathy P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucl Acids Res 1987; 15: 7155-74.
10. Green PM, Rowley G, Giannelli F. Unusual expression of the F9 gene in peripheral lymphocytes hinders investigation of F9 mRNA in hemo-philia B patients. J Thromb Haemost 2003; 1: 2675-6.
11. Green PM, Montandon AJ, Ljung R, Nilsson IM, Giannelli F. Haplotype analysis of identical factorIX mutants using PCR. Thromb Haemost 1992; 67: 66-9.
12. Rowley G, Saad S, Giannelli F, Green PM. Ultrarapid mutation detec-tion by multiplex, solid-phase chemical cleavage. Genomics 1995; 30: 574-82.
13. Anagnostopoulos T, Green PM, Rowley G, Lewis CM, Giannelli F. DNA variation in a 5-Mb region of the X chromosome and estimates of sex-specific/type-specific mutation rates. Am J Hum Genet 1999; 64: 508-17.
14. International SNP Map Working Group. A map of human genome sequence variation containing 1.42 million single nucleotide poly-morphisms. Nature 2001; 409: 928-33.
15. Harris EE, Hey J. Human populations show reduced DNA sequence variation at the F9 locus. Current Biol 2001; 11: 774-8.
16. Giannelli F, Anagnostopoulos T, Green PM. Mutation rates in humans. II. Sporadic mutation-specific rates and rate of detrimental human muta-tions inferred from hemophilia B. Am J Hum Genet 1999; 65: 1580-7.
17. Camerino G, Grzeschik KH, Jaye M, De La Salle H, Tolstoshev P, Lecocq JP, Heilig R, Mandel JL. Regional localisation on the human X chromosome and polymorphism of the coagulation factor IX gene (hemophilia B locus). Proc Natl Acad Sci USA 1984; 81: 498-502.
18. Winship PR, Anson DS, Rizza CR, Brownlee GG. Carrier detection in haemophilia B using two further intragenic restriction fragment length polymorphisms. Nucl Acids Res 1984; 12: 8861-72.
19. McGraw RA, Davis LM, Noyes CM, Lundblad RL, Roberts HR, Graham JB, Stafford DW. Evidence for a prevalent dimorphism in the activation peptide of human coagulation factorIX. Proc Natl Acad Sci USA 1985; 82: 2847-51.
20. Winship PR, Rees DJ, Alkan M. Detection of polymorphisms at cytosine phosphoguanadine dinucleotides and diagnosis of haemophilia B carriers. Lancet 1989; 1: 631-4.
21. CooperDN, Krawczak M. Human Gene Mutation. Oxford: BIOS Scientific Publishers, 1993.
22. Risch N, de Leon D, Ozelius L, Kramer P, Almasy L, Singer B, Fahn S, Breakefield X, Bressman S. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founderpopulation. Nat Genet 1995; 9: 152-9.
23. Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King MC, GoldgarD, et al. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 1996; 58: 271-80.
24. Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King MC, GoldgarD, et al. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 1998; 62: 1381-8.